Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
Phase 2 Completed
ASCR
Phase 1 Completed
14 enrolled
Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer
Phase 2 Completed
Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer
Phase 2 Completed
18 enrolled
Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma
Phase 1/2 Completed
40 enrolled
GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer
Phase 2 Completed
28 enrolled 7 charts
Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
Phase 2 Completed
73 enrolled 16 charts
Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)
Phase 2 Completed
40 enrolled 8 charts
An Open Trial to Assess the Efficacy and Safety of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer
Phase 2 Completed
30 enrolled
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy
Phase 2 Completed
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate
Phase 2 Completed
60 enrolled
Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma
Phase 1/2 Completed
15 enrolled
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Phase 1 Completed
26 enrolled
A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma
Phase 2 Completed
30 enrolled
Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer
Phase 3 Completed
A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer
Phase 2 Completed
64 enrolled